Drug intelligence / Profile preview

BT3

Development stage: Preclinical
Lead developer: Bycus Therapeutics
Modality: Therapeutic Enzymes → Recombinant Proteins and Enzymes

Overview

BT3 is an early-stage enzyme candidate, specifically a protease, under development by Bycus Therapeutics. Within the company's pipeline, it is categorized alongside other enzyme-based therapies such as BT2 (a nuclease) and BT4 (another protease). As a protease, BT3 is designed to catalyze the proteolysis of specific protein targets, though its exact molecular target, therapeutic indication, and clinical stage have not been publicly disclosed. It represents part of Bycus Therapeutics' broader focus on developing novel molecules and enzymes for various therapeutic areas.

Beyond the preview

Go deeper on BT3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BT3.

Explore the full profile